Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Apr 1;101(7):1421–1430. doi: 10.1172/JCI1349

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.

J Schirra 1, K Sturm 1, P Leicht 1, R Arnold 1, B Göke 1, M Katschinski 1
PMCID: PMC508720  PMID: 9525985

Abstract

The gastrointestinal hormone, glucagon-like peptide-1(7-36)amide (GLP-1) is released after a meal. The potency of synthetic GLP-1 in stimulating insulin secretion and in inhibiting glucagon secretion indicates the putative physiological function of GLP-1. In vitro, the nonmammalian peptide, exendin(9-39)amide [ex(9-39)NH2], is a specific and competitive antagonist of GLP-1. This in vivo study examined the efficacy of ex(9-39)NH2 as an antagonist of exogenous GLP-1 and the physiological role of endogenous GLP-1. Six healthy volunteers underwent 10 experiments in random order. In each experiment, a 30-min period of euglycemia was followed by an intravenous infusion of glucose for 150 min that established a stable hyperglycemia of 8 mmol/liter. There was a concomitant intravenous infusion of one of the following: (1) saline, (2) GLP-1 (for 60 min at 0.3 pmol . kg-1 . min-1 that established physiological postprandial plasma levels, and for another 60 min at 0.9 pmol . kg-1 . min-1 to induce supraphysiological plasma levels), (3-5) ex(9-39)NH2 at 30, 60, or 300 pmol . kg-1 . min-1 + GLP-1, (6-8) ex(9-39)NH2 at 30, 60, or 300 pmol . kg-1 . min-1 + saline, (9 and 10) GIP (glucose-dependent insulinotropic peptide; for 60 min at 0.8 pmol . kg-1 . min-1, with saline or ex(9-39)NH2 at 300 pmol . kg-1 . min-1). Each volunteer received each of these concomitant infusions on separate days. ex(9-39)NH2 dose-dependently reduced the insulinotropic action of GLP-1 with the inhibitory effect declining with increasing doses of GLP-1. ex(9-39)NH2 at 300 pmol . kg-1 . min-1 blocked the insulinotropic effect of physiological doses of GLP-1 and completely antagonized the glucagonostatic effect at both doses of GLP-1. Given alone, this load of ex(9-39)NH2 increased plasma glucagon levels during euglycemia and hyperglycemia. It had no effect on plasma levels of insulin during euglycemia but decreased plasma insulin during hyperglycemia. ex(9-39)NH2 did not alter GIP-stimulated insulin secretion. These data indicate that in humans, ex(9-39)NH2 is a potent GLP-1 antagonist without any agonistic properties. The pancreatic A cell is under a tonic inhibitory control of GLP-1. At hyperglycemia, the B cell is under a tonic stimulatory control of GLP-1.

Full Text

The Full Text of this article is available as a PDF (284.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brubaker P. L. Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology. 1991 Jun;128(6):3175–3182. doi: 10.1210/endo-128-6-3175. [DOI] [PubMed] [Google Scholar]
  2. D'Alessio D. A., Prigeon R. L., Ensinck J. W. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes. 1995 Dec;44(12):1433–1437. doi: 10.2337/diab.44.12.1433. [DOI] [PubMed] [Google Scholar]
  3. D'Alessio D. A., Vogel R., Prigeon R., Laschansky E., Koerker D., Eng J., Ensinck J. W. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest. 1996 Jan 1;97(1):133–138. doi: 10.1172/JCI118380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. DeFronzo R. A., Tobin J. D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979 Sep;237(3):E214–E223. doi: 10.1152/ajpendo.1979.237.3.E214. [DOI] [PubMed] [Google Scholar]
  5. Ding W. G., Renström E., Rorsman P., Buschard K., Gromada J. Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes. 1997 May;46(5):792–800. doi: 10.2337/diab.46.5.792. [DOI] [PubMed] [Google Scholar]
  6. Drucker D. J., Philippe J., Mojsov S., Chick W. L., Habener J. F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A. 1987 May;84(10):3434–3438. doi: 10.1073/pnas.84.10.3434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Elahi D., McAloon-Dyke M., Fukagawa N. K., Meneilly G. S., Sclater A. L., Minaker K. L., Habener J. F., Andersen D. K. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept. 1994 Apr 14;51(1):63–74. doi: 10.1016/0167-0115(94)90136-8. [DOI] [PubMed] [Google Scholar]
  8. Fehmann H. C., Göke R., Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev. 1995 Jun;16(3):390–410. doi: 10.1210/edrv-16-3-390. [DOI] [PubMed] [Google Scholar]
  9. Fehmann H. C., Habener J. F. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line. FEBS Lett. 1991 Feb 25;279(2):335–340. doi: 10.1016/0014-5793(91)80182-3. [DOI] [PubMed] [Google Scholar]
  10. Fehmann H. C., Habener J. F. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology. 1992 Jan;130(1):159–166. doi: 10.1210/endo.130.1.1309325. [DOI] [PubMed] [Google Scholar]
  11. Fehmann H. C., Hering B. J., Wolf M. J., Brandhorst H., Brandhorst D., Bretzel R. G., Federlin K., Göke B. The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas. 1995 Aug;11(2):196–200. doi: 10.1097/00006676-199508000-00014. [DOI] [PubMed] [Google Scholar]
  12. Gremlich S., Porret A., Hani E. H., Cherif D., Vionnet N., Froguel P., Thorens B. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes. 1995 Oct;44(10):1202–1208. doi: 10.2337/diab.44.10.1202. [DOI] [PubMed] [Google Scholar]
  13. Gros L., Thorens B., Bataille D., Kervran A. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology. 1993 Aug;133(2):631–638. doi: 10.1210/endo.133.2.8102095. [DOI] [PubMed] [Google Scholar]
  14. Gutniak M., Orskov C., Holst J. J., Ahrén B., Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992 May 14;326(20):1316–1322. doi: 10.1056/NEJM199205143262003. [DOI] [PubMed] [Google Scholar]
  15. Göke R., Fehmann H. C., Göke B. Glucagon-like peptide-1(7-36) amide is a new incretin/enterogastrone candidate. Eur J Clin Invest. 1991 Apr;21(2):135–144. doi: 10.1111/j.1365-2362.1991.tb01802.x. [DOI] [PubMed] [Google Scholar]
  16. Göke R., Fehmann H. C., Linn T., Schmidt H., Krause M., Eng J., Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem. 1993 Sep 15;268(26):19650–19655. [PubMed] [Google Scholar]
  17. Göke R., Wagner B., Fehmann H. C., Göke B. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med (Berl) 1993;193(2):97–103. doi: 10.1007/BF02576216. [DOI] [PubMed] [Google Scholar]
  18. Heller R. S., Aponte G. W. Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide. Am J Physiol. 1995 Dec;269(6 Pt 1):G852–G860. doi: 10.1152/ajpgi.1995.269.6.G852. [DOI] [PubMed] [Google Scholar]
  19. Heller R. S., Kieffer T. J., Habener J. F. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes. 1997 May;46(5):785–791. doi: 10.2337/diab.46.5.785. [DOI] [PubMed] [Google Scholar]
  20. Holz G. G., 4th, Kühtreiber W. M., Habener J. F. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature. 1993 Jan 28;361(6410):362–365. doi: 10.1038/361362a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kolligs F., Fehmann H. C., Göke R., Göke B. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes. 1995 Jan;44(1):16–19. doi: 10.2337/diab.44.1.16. [DOI] [PubMed] [Google Scholar]
  22. Komatsu R., Matsuyama T., Namba M., Watanabe N., Itoh H., Kono N., Tarui S. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes. 1989 Jul;38(7):902–905. doi: 10.2337/diab.38.7.902. [DOI] [PubMed] [Google Scholar]
  23. Kreymann B., Williams G., Ghatei M. A., Bloom S. R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987 Dec 5;2(8571):1300–1304. doi: 10.1016/s0140-6736(87)91194-9. [DOI] [PubMed] [Google Scholar]
  24. Maruyama H., Tominaga M., Bolli G., Orci L., Unger R. H. The alpha cell response to glucose change during perfusion of anti-insulin serum in pancreas isolated from normal rats. Diabetologia. 1985 Nov;28(11):836–840. doi: 10.1007/BF00291074. [DOI] [PubMed] [Google Scholar]
  25. Montrose-Rafizadeh C., Yang H., Rodgers B. D., Beday A., Pritchette L. A., Eng J. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem. 1997 Aug 22;272(34):21201–21206. doi: 10.1074/jbc.272.34.21201. [DOI] [PubMed] [Google Scholar]
  26. Nathan D. M., Schreiber E., Fogel H., Mojsov S., Habener J. F. Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care. 1992 Feb;15(2):270–276. doi: 10.2337/diacare.15.2.270. [DOI] [PubMed] [Google Scholar]
  27. Nauck M. A., Bartels E., Orskov C., Ebert R., Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab. 1993 Apr;76(4):912–917. doi: 10.1210/jcem.76.4.8473405. [DOI] [PubMed] [Google Scholar]
  28. Nauck M. A., Heimesaat M. M., Orskov C., Holst J. J., Ebert R., Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993 Jan;91(1):301–307. doi: 10.1172/JCI116186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. O'Halloran D. J., Nikou G. C., Kreymann B., Ghatei M. A., Bloom S. R. Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man. J Endocrinol. 1990 Jul;126(1):169–173. doi: 10.1677/joe.0.1260169. [DOI] [PubMed] [Google Scholar]
  30. Rai A., Singh G., Raffaniello R., Eng J., Raufman J. P. Actions of Helodermatidae venom peptides and mammalian glucagon-like peptides on gastric chief cells. Am J Physiol. 1993 Jul;265(1 Pt 1):G118–G125. doi: 10.1152/ajpgi.1993.265.1.G118. [DOI] [PubMed] [Google Scholar]
  31. Raufman J. P., Singh L., Singh G., Eng J. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem. 1992 Oct 25;267(30):21432–21437. [PubMed] [Google Scholar]
  32. Schirra J., Katschinski M., Weidmann C., Schäfer T., Wank U., Arnold R., Göke B. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest. 1996 Jan 1;97(1):92–103. doi: 10.1172/JCI118411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schirra J., Kuwert P., Wank U., Leicht P., Arnold R., Göke B., Katschinski M. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians. 1997 Jan;109(1):84–97. [PubMed] [Google Scholar]
  34. Schirra J., Leicht P., Hildebrand P., Beglinger C., Arnold R., Göke B., Katschinski M. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus. J Endocrinol. 1998 Jan;156(1):177–186. doi: 10.1677/joe.0.1560177. [DOI] [PubMed] [Google Scholar]
  35. Schjoldager B. T., Mortensen P. E., Christiansen J., Orskov C., Holst J. J. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci. 1989 May;34(5):703–708. doi: 10.1007/BF01540341. [DOI] [PubMed] [Google Scholar]
  36. Schmid R., Schusdziarra V., Aulehner R., Weigert N., Classen M. Comparison of GLP-1 (7-36amide) and GIP on release of somatostatin-like immunoreactivity and insulin from the isolated rat pancreas. Z Gastroenterol. 1990 Jun;28(6):280–284. [PubMed] [Google Scholar]
  37. Tang-Christensen M., Larsen P. J., Göke R., Fink-Jensen A., Jessop D. S., Møller M., Sheikh S. P. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol. 1996 Oct;271(4 Pt 2):R848–R856. doi: 10.1152/ajpregu.1996.271.4.R848. [DOI] [PubMed] [Google Scholar]
  38. Thorens B., Porret A., Bühler L., Deng S. P., Morel P., Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes. 1993 Nov;42(11):1678–1682. doi: 10.2337/diab.42.11.1678. [DOI] [PubMed] [Google Scholar]
  39. Turton M. D., O'Shea D., Gunn I., Beak S. A., Edwards C. M., Meeran K., Choi S. J., Taylor G. M., Heath M. M., Lambert P. D. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996 Jan 4;379(6560):69–72. doi: 10.1038/379069a0. [DOI] [PubMed] [Google Scholar]
  40. Wang Z., Wang R. M., Owji A. A., Smith D. M., Ghatei M. A., Bloom S. R. Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest. 1995 Jan;95(1):417–421. doi: 10.1172/JCI117671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Wettergren A., Petersen H., Orskov C., Christiansen J., Sheikh S. P., Holst J. J. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol. 1994 Jun;29(6):501–505. doi: 10.3109/00365529409092462. [DOI] [PubMed] [Google Scholar]
  42. Wheeler M. B., Gelling R. W., McIntosh C. H., Georgiou J., Brown J. C., Pederson R. A. Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology. 1995 Oct;136(10):4629–4639. doi: 10.1210/endo.136.10.7664683. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES